Send to

Choose Destination
Chonnam Med J. 2014 Aug;50(2):37-44. doi: 10.4068/cmj.2014.50.2.37. Epub 2014 Aug 20.

Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant Acinetobacter infections.

Author information

Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.


Carbapenem-resistant Acinetobacter species are increasingly recognized as major nosocomial pathogens, especially in patients with critical illnesses or in intensive care. The ability of these organisms to accumulate diverse mechanisms of resistance limits the available therapeutic agents, makes the infection difficult to treat, and is associated with a greater risk of death. In this review, we provide an update on the epidemiology, resistance mechanisms, infection control measures, treatment, and outcomes of carbapenem-resistant Acinetobacter infections.


Acinetobacter baumannii; Colistin; Drug therapy

Supplemental Content

Full text links

Icon for Chonnam National University Medical School Icon for PubMed Central
Loading ...
Support Center